In a proxy filing, Sarepta Therapeutics (NASDAQ: SRPT) said it has withdrawn the portion of proposal four requesting an increase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE